Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Disparities persist as Blacks, Hispanics, and females are underrepresented in clinical trials for CLL and other blood cancers.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
Preclinical research shows that LP-168 inhibits BTK in CLL cells regardless of whether resistance mutations exist.
The FDA is revising clinical trials to improve safety, and CLL Society’s Dr. Brian Koffman was asked to serve as the patient representative
A new clinical trial is recruiting patients with relapsed / refractory B-cell cancers to test the safety of a new experimental MALT1 inhibitor.
A new phase 3 clinical trial is testing sonrotoclax, a new BCL2 inhibitor, in combination with zanubrutinib for CLL.
Improving global representation in clinical trials is important for addressing enduring health disparities in underrepresented regions.
Despite mild persistent night sweats and disturbed sleep, I am enjoying and learning much at iwCLL (international workshop on CLL) in Boston.
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
One click to our most popular content.
